REGENXBIO Inc.
RGNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $83 | $90 | $113 | $470 |
| % Growth | -7.7% | -19.9% | -76% | – |
| Cost of Goods Sold | $34 | $37 | $55 | $52 |
| Gross Profit | $50 | $53 | $58 | $419 |
| % Margin | 59.7% | 58.8% | 51.6% | 89% |
| R&D Expenses | $209 | $232 | $242 | $181 |
| G&A Expenses | $77 | $88 | $85 | $79 |
| SG&A Expenses | $77 | $88 | $85 | $79 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2 | $0 | -$7 | -$2 |
| Operating Expenses | $283 | $321 | $321 | $259 |
| Operating Income | -$233 | -$268 | -$263 | $160 |
| % Margin | -280% | -297.1% | -233.2% | 34% |
| Other Income/Exp. Net | $6 | $4 | -$18 | -$19 |
| Pre-Tax Income | -$227 | -$264 | -$280 | $141 |
| Tax Expense | $0 | -$0 | -$0 | $13 |
| Net Income | -$227 | -$263 | -$280 | $128 |
| % Margin | -272.5% | -292% | -248.7% | 27.2% |
| EPS | -4.59 | -6.02 | -6.5 | 3.01 |
| % Growth | 23.8% | 7.4% | -315.9% | – |
| EPS Diluted | -4.59 | -6.02 | -6.5 | 2.91 |
| Weighted Avg Shares Out | 50 | 44 | 43 | 42 |
| Weighted Avg Shares Out Dil | 50 | 44 | 43 | 44 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $13 | $7 | $23 | $26 |
| Depreciation & Amortization | $16 | $17 | $13 | $10 |
| EBITDA | -$198 | -$239 | -$244 | $170 |
| % Margin | -237.9% | -265.4% | -216.7% | 36% |